Core Laboratories マネジメント
マネジメント 基準チェック /34
Core Laboratoriesの CEO はLarry Brunoで、 Feb2018年に任命され、 の在任期間は 8.25年です。 の年間総報酬は$ 4.98Mで、 17.8%給与と82.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.56%を直接所有しており、その価値は$ 3.66M 。経営陣と取締役会の平均在任期間はそれぞれ5.6年と5年です。
主要情報
Larry Bruno
最高経営責任者
US$5.0m
報酬総額
| CEO給与比率 | 17.81% |
| CEO在任期間 | 8.3yrs |
| CEOの所有権 | 0.6% |
| 経営陣の平均在職期間 | 5.6yrs |
| 取締役会の平均在任期間 | 5yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).
ナラティブの更新 • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).ナラティブの更新 • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking Alphaナラティブの更新 • Jan 26
CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.ナラティブの更新 • Jan 11
CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.ナラティブの更新 • Dec 14
CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.分析記事 • Nov 21
A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...ナラティブの更新 • Sep 10
Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.分析記事 • Sep 10
Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...分析記事 • Jul 24
We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 03
Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...分析記事 • Jun 12
Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...分析記事 • Apr 04
Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...分析記事 • Jan 21
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...分析記事 • Jan 03
Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...分析記事 • Dec 09
Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...分析記事 • Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
新しいナラティブ • Sep 24
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.分析記事 • Sep 19
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...分析記事 • Aug 14
What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...分析記事 • Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jun 25
These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...分析記事 • May 02
It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...分析記事 • Mar 26
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?
Key Insights The projected fair value for Core Laboratories is US$22.93 based on 2 Stage Free Cash Flow to Equity Core...分析記事 • Mar 02
Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price
Core Laboratories Inc.'s ( NYSE:CLB ) price-to-earnings (or "P/E") ratio of 19.8x might make it look like a sell right...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$29m |
| Dec 31 2025 | US$5m | US$887k | US$30m |
| Sep 30 2025 | n/a | n/a | US$32m |
| Jun 30 2025 | n/a | n/a | US$30m |
| Mar 31 2025 | n/a | n/a | US$28m |
| Dec 31 2024 | US$6m | US$887k | US$31m |
| Sep 30 2024 | n/a | n/a | US$26m |
| Jun 30 2024 | n/a | n/a | US$24m |
| Mar 31 2024 | n/a | n/a | US$38m |
| Dec 31 2023 | US$8m | US$887k | US$37m |
| Sep 30 2023 | n/a | n/a | US$41m |
| Jun 30 2023 | n/a | n/a | US$39m |
| Mar 31 2023 | n/a | n/a | US$24m |
| Dec 31 2022 | US$6m | US$820k | US$19m |
| Sep 30 2022 | n/a | n/a | US$15m |
| Jun 30 2022 | n/a | n/a | US$9m |
| Mar 31 2022 | n/a | n/a | US$10m |
| Dec 31 2021 | US$7m | US$820k | US$20m |
| Sep 30 2021 | n/a | n/a | US$31m |
| Jun 30 2021 | n/a | n/a | US$33m |
| Mar 31 2021 | n/a | n/a | US$19m |
| Dec 31 2020 | US$5m | US$820k | -US$97m |
| Sep 30 2020 | n/a | n/a | -US$101m |
| Jun 30 2020 | n/a | n/a | -US$80m |
| Mar 31 2020 | n/a | n/a | -US$55m |
| Dec 31 2019 | US$3m | US$531k | US$94m |
報酬と市場: Larryの 総報酬 ($USD 4.98M ) は、 US市場 ($USD 3.70M ) の同規模の企業の平均を上回っています。
報酬と収益: Larryの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Larry Bruno (65 yo)
8.3yrs
在職期間
US$4,980,491
報酬
Mr. Lawrence V. Bruno, also known as Larry, serves as Chairman of Board and Chief Exertive Officer at Core Core Laboratories Inc. since May 20, 2020. He has been Director of Core Laboratories N.V. since Ma...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman of the Board | 8.3yrs | US$4.98m | 0.56% $ 3.7m | |
| Senior VP & CFO | 8yrs | US$1.86m | 0.24% $ 1.6m | |
| Senior Vice President of Corporate Development & Investor Relations | 9.8yrs | US$1.14m | 0.072% $ 472.5k | |
| Senior VP | 4.8yrs | US$1.15m | 0.063% $ 415.6k | |
| VP, Treasurer & Chief Accounting Officer | 2.2yrs | データなし | 0.019% $ 124.6k | |
| Vice President of People | 2.3yrs | データなし | データなし | |
| Senior Vice President of Production Enhancement & Business Development | 6.3yrs | データなし | データなし | |
| President of Owen Oil Tools | 1.5yrs | データなし | データなし |
5.6yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: CLBの経営陣は経験豊富で経験豊富です（平均在職期間は5.6年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman of the Board | 8yrs | US$4.98m | 0.56% $ 3.7m | |
| Independent Director | 2.9yrs | US$201.80k | 0.052% $ 338.5k | |
| Independent Director | 1yr | US$129.41k | 0.018% $ 114.7k | |
| Independent Director | 4.3yrs | US$205.55k | 0.064% $ 416.5k | |
| Independent Director | 6yrs | US$215.55k | 0.11% $ 711.4k | |
| Lead Independent Director | 10.3yrs | US$253.05k | 0.12% $ 773.5k | |
| Independent Director | 5yrs | US$218.05k | 0.073% $ 477.7k |
5.0yrs
平均在職期間
67yo
平均年齢
経験豊富なボード: CLBの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 05:28 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Core Laboratories Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30
| アナリスト | 機関 |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |